Table 1.
Demographic and clinical data
| All patients (n = 1004) |
No CME (n = 508) |
CME (n = 496) |
P* | |
|---|---|---|---|---|
| Sex ratio (M : F) | 444 : 560 | 208 : 300 | 236 : 260 | 0.040 |
| Age (years), mean(s.d.) | 72.2 (10.9) | 73.0 (1.3) | 71.4 (11.3) | 0.020† |
| 0–40 | 12 (1.2) | 6 (50.0) | 6 (50.0) | 0.024† |
| 41–60 | 130 (12.9) | 51 (39.2) | 79 (60.8) | |
| 61–80 | 635 (63.2) | 324 (51.0) | 311 (49.0) | |
| >80 | 227 (22.6) | 127 (55.9) | 100 (44.1) | |
| BMI (kg/m2), mean(s.d.) | 26.7 (4.9) | 26.8 (4.9) | 26.6 (5.0) | 0.570 |
| −18.5 | 13 (1.3) | 4 (30.8) | 9 (69.2) | 0.188 |
| 18–25 | 382 (38.0) | 195 (51.0) | 187 (49.0) | |
| 25–30 | 359 (35.8) | 170 (47.4) | 189 (52.6) | |
| 30- | 194 (19.3) | 107 (55.2) | 87 (44.8) | |
| Not available | 56 (5.6) | 32 (57.1) | 24 (42.9) | |
| Adjuvant chemotherapy | ||||
| UICC stage I | 1.000 | |||
| Yes | 2 (0.7) | 1 (50.0) | 1 (50.0) | |
| No | 235 (77.8) | 109 (46.4) | 126 (53.6) | |
| Not available | 65 (21.5) | 41 (63.1) | 24 (36.9) | |
| UICC stage II | 0.225 | |||
| Yes | 38 (9.6) | 21 (55.3) | 17 (44.7) | |
| No | 265 (67.3) | 117 (44.2) | 148 (55.8) | |
| Not available | 91 (23.1) | 61 (67.0) | 30 (33.0) | |
| UICC stage III | 0.888 | |||
| Yes | 180 (59.2) | 88 (48.9) | 92 (51.1) | |
| No | 70 (23.0) | 33 (47.1) | 37 (52.9) | |
| Not available | 54 (17.8) | 36 (66.7) | 18 (33.3) | |
| Tumour location | 0.601 | |||
| Ascending colon | 512 (51.0) | 256 (50.0) | 256 (50.0) | |
| Hepatic flexure | 72 (7.2) | 33 (45.8) | 39 (54.2) | |
| Caecum | 414 (41.2) | 215 (51.9) | 199 (48.1) | |
| Not available | 6 (0.6) | 4 (66.7) | 2 (33.3) | |
| Surgical approach | 0.148 | |||
| Laparoscopic | 204 (20.3) | 103 (50.5) | 101 (49.5) | |
| Open | 764 (76.1) | 379 (49.6) | 385 (50.4) | |
| Converted | 13 (1.3) | 10 (76.9) | 3 (23.1) | |
| Not available | 23 (2.3) | 16 (69.6) | 7 (30.4) | |
| ASA fitness grade | 0.226 | |||
| I | 63 (6.3) | 39 (61.9) | 24 (38.1) | |
| II | 554 (55.2) | 269 (48.6) | 285 (51.4) | |
| III | 333 (33.2) | 168 (50.5) | 165 (49.5) | |
| IV | 14 (1.4) | 6 (42.9) | 8 (57.1) | |
| Not available | 40 (4.0) | 26 (65.0) | 14 (35.0) |
Values are n (%) unless otherwise indicated. Rates of chemotherapy were 62.5 per cent in the complete mesocolic excision (CME) group and 56.0 per cent in non-CME group in stage III, and 8.7 and 10.5 per cent respectively in stage II. *χ2test, except †? test.